Cancer Causes & Control

, 20:741

Metabolic factors and subsequent risk of hepatocellular carcinoma by hepatitis virus infection status: a large-scale population-based cohort study of Japanese men and women (JPHC Study Cohort II)

  • Manami Inoue
  • Norie Kurahashi
  • Motoki Iwasaki
  • Yasuhito Tanaka
  • Masashi Mizokami
  • Mitsuhiko Noda
  • Shoichiro Tsugane
  • for the Japan Public Health Center-based Prospective Study Group
Original Paper



The association between metabolic factors and hepatocellular carcinoma (HCC) has not been well clarified. We prospectively examined whether metabolic factors predicts the subsequent risk of HCC in the Japan Public Health Center-based Prospective Study Cohort II, in consideration of hepatitis virus infection status.


A total of 17,590 subjects aged 40–69 participating in a questionnaire and health checkup survey during 1993–1994 were followed for incidence of HCC through 2006. A total of 102 cases of HCC were newly documented. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated for metabolic factors controlling for potential confounding factors.


The presence of metabolic factors in the aggregate was associated with a significantly increased risk of HCC, especially with hepatitis virus infection. HCC was positively associated particularly with high glucose (HR = 1.75, CI = 1.11–2.74) and overweight (HR = 2.22, CI = 1.42–3.48). Results were similar when analyses were limited to subjects with HCV infection.


Although metabolic factors in the aggregate may be associated with an increased risk of HCC, the main contributors to this association under HCV infection appear to be overweight and high glucose. Improvement of these factors may be a crucial target in preventing progression to HCC in those with HCV infection.


Metabolic factor Hepatocellular carcinoma Cohort study Overweight High glucose 


  1. 1.
    Lonardo A, Loria P, Carulli N (2008) Dysmetabolic changes associated with HCV: a distinct syndrome? Intern Emerg Med 3:99–108. doi:10.1007/s11739-008-0127-1 PubMedCrossRefGoogle Scholar
  2. 2.
    Bugianesi E (2005) Review article: steatosis, the metabolic syndrome and cancer. Aliment Pharmacol Ther 22(Suppl 2):40–43. doi:10.1111/j.1365-2036.2005.02594.x PubMedCrossRefGoogle Scholar
  3. 3.
    Bugianesi E, Zannoni C, Vanni E, Marzocchi R, Marchesini G (2004) Non-alcoholic fatty liver and insulin resistance: a cause–effect relationship? Dig Liver Dis 36:165–173. doi:10.1016/j.dld.2003.12.008 PubMedCrossRefGoogle Scholar
  4. 4.
    El-Serag HB, Hampel H, Javadi F (2006) The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 4:369–380. doi:10.1016/j.cgh.2005.12.007 PubMedCrossRefGoogle Scholar
  5. 5.
    El-Serag HB, Hampel H, Javadi F (2007) The Editorial Board of the Cancer Statistics in Japan. Cancer statistics in Japan 2007. Foundation for Promotion of Cancer Research (FPFR), TokyoGoogle Scholar
  6. 6.
    Marugame T, Matsuda T, Kamo K, Katanoda K, Ajiki W, Sobue T (2007) Cancer incidence and incidence rates in Japan in 2001 based on the data from 10 population-based cancer registries. Jpn J Clin Oncol 37:884–891. doi:10.1093/jjco/hym112 PubMedCrossRefGoogle Scholar
  7. 7.
    Shiratori Y, Shiina S, Imamura M, Kato N, Kanai F, Okudaira T, Teratani T, Tohgo G, Toda N, Ohashi M et al (1995) Characteristic difference of hepatocellular carcinoma between hepatitis B- and C-viral infection in Japan. Hepatology 22:1027–1033PubMedCrossRefGoogle Scholar
  8. 8.
    Eckel RH, Grundy SM, Zimmet PZ (2005) The metabolic syndrome. Lancet 365:1415–1428. doi:10.1016/S0140-6736(05)66378-7 PubMedCrossRefGoogle Scholar
  9. 9.
    Russo A, Autelitano M, Bisanti L (2008) Metabolic syndrome and cancer risk. Eur J Cancer 44:293–297. doi:10.1016/j.ejca.2007.11.005 PubMedCrossRefGoogle Scholar
  10. 10.
    Chen CL, Yang HI, Yang WS, Liu CJ, Chen PJ, You SL, Wang LY, Sun CA, Lu SN, Chen DS, Chen CJ (2008) Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 135:111–121. doi:10.1053/j.gastro.2008.03.073 PubMedCrossRefGoogle Scholar
  11. 11.
    Inoue M, Iwasaki M, Otani T, Sasazuki S, Noda M, Tsugane S (2006) Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med 166:1871–1877. doi:10.1001/archinte.166.17.1871 PubMedCrossRefGoogle Scholar
  12. 12.
    Kuriki K, Hirose K, Tajima K (2007) Diabetes and cancer risk for all and specific sites among Japanese men and women. Eur J Cancer Prev 16:83–89. doi:10.1097/01.cej.0000228404.37858.40 PubMedCrossRefGoogle Scholar
  13. 13.
    Lai MS, Hsieh MS, Chiu YH, Chen TH (2006) Type 2 diabetes and hepatocellular carcinoma: a cohort study in high prevalence area of hepatitis virus infection. Hepatology 43:1295–1302. doi:10.1002/hep.21208 PubMedCrossRefGoogle Scholar
  14. 14.
    Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM (2005) Fasting serum glucose level and cancer risk in Korean men and women. JAMA 293:194–202. doi:10.1001/jama.293.2.194 PubMedCrossRefGoogle Scholar
  15. 15.
    Yuan JM, Govindarajan S, Arakawa K, Yu MC (2004) Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S. Cancer 101:1009–1017. doi:10.1002/cncr.20427 PubMedCrossRefGoogle Scholar
  16. 16.
    Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL, Beasley P, Patt YZ (2002) Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 36:1206–1213. doi:10.1053/jhep.2002.36780 PubMedCrossRefGoogle Scholar
  17. 17.
    El-Serag HB, Richardson PA, Everhart JE (2001) The role of diabetes in hepatocellular carcinoma: a case–control study among United States Veterans. Am J Gastroenterol 96:2462–2467. doi:10.1111/j.1572-0241.2001.04054.x PubMedCrossRefGoogle Scholar
  18. 18.
    Lagiou P, Kuper H, Stuver SO, Tzonou A, Trichopoulos D, Adami HO (2000) Role of diabetes mellitus in the etiology of hepatocellular carcinoma. J Natl Cancer Inst 92:1096–1099. doi:10.1093/jnci/92.13.1096 PubMedCrossRefGoogle Scholar
  19. 19.
    La Vecchia C, Negri E, Decarli A, Franceschi S (1997) Diabetes mellitus and the risk of primary liver cancer. Int J Cancer 73:204–207. doi:10.1002/(SICI)1097-0215(19971009)73:2<204::AID-IJC7>3.0.CO;2-#PubMedCrossRefGoogle Scholar
  20. 20.
    Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB (2005) Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 54:533–539. doi:10.1136/gut.2004.052167 PubMedCrossRefGoogle Scholar
  21. 21.
    Ohishi W, Fujiwara S, Cologne JB, Suzuki G, Akahoshi M, Nishi N, Takahashi I, Chayama K (2008) Risk factors for hepatocellular carcinoma in a Japanese population: a nested case–control study. Cancer Epidemiol Biomarkers Prev 17:846–854. doi:10.1158/1055-9965.EPI-07-2806 PubMedCrossRefGoogle Scholar
  22. 22.
    Samanic C, Gridley G, Chow WH, Lubin J, Hoover RN, Fraumeni JF Jr (2004) Obesity and cancer risk among white and black United States veterans. Cancer Causes Control 15:35–43. doi:10.1023/ PubMedCrossRefGoogle Scholar
  23. 23.
    Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625–1638. doi:10.1056/NEJMoa021423 PubMedCrossRefGoogle Scholar
  24. 24.
    Moller H, Mellemgaard A, Lindvig K, Olsen JH (1994) Obesity and cancer risk: a Danish record-linkage study. Eur J Cancer 30A:344–350. doi:10.1016/0959-8049(94)90254-2 PubMedCrossRefGoogle Scholar
  25. 25.
    Rapp K, Schroeder J, Klenk J, Stoehr S, Ulmer H, Concin H, Diem G, Oberaigner W, Weiland SK (2005) Obesity and incidence of cancer: a large cohort study of over 145,000 adults in Austria. Br J Cancer 93:1062–1067. doi:10.1038/sj.bjc.6602819 PubMedCrossRefGoogle Scholar
  26. 26.
    Wolk A, Gridley G, Svensson M, Nyren O, McLaughlin JK, Fraumeni JF, Adam HO (2001) A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control 12:13–21. doi:10.1023/A:1008995217664 PubMedCrossRefGoogle Scholar
  27. 27.
    Tsugane S, Sobue T (2001) Baseline survey of JPHC study–design and participation rate, Japan Public Health Center-based Prospective Study on Cancer and Cardiovascular Diseases. J Epidemiol 11:S24–S29PubMedGoogle Scholar
  28. 28.
    Iida M, Sato S, Nakamura M (2001) Standardization of laboratory test in the JPHC study, Japan Public Health Center-based Prospective Study on Cancer and Cardiovascular Diseases. J Epidemiol 11:S81–S86PubMedGoogle Scholar
  29. 29.
    Nakamura M, Sato S, Shimamoto T (2003) Improvement in Japanese clinical laboratory measurements of total cholesterol and HDL-cholesterol by the US Cholesterol Reference Method Laboratory Network. J Atheroscler Thromb 10:145–153PubMedGoogle Scholar
  30. 30.
    Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112:2735–2752. doi:10.1161/CIRCULATIONAHA.105.169404 PubMedCrossRefGoogle Scholar
  31. 31.
    Alberti KG, Zimmet P, Shaw J (2006) Metabolic syndrome—a new world-wide definition, A Consensus Statement from the International Diabetes Federation. Diabet Med 23:469–480. doi:10.1111/j.1464-5491.2006.01858.x PubMedCrossRefGoogle Scholar
  32. 32.
    Examination Committee of Criteria for ‘Obesity Disease’ in Japan; Japan Society for the Study of Obesity (2006) New criteria for ‘obesity disease’ in Japan. Circ J 66:987–992. doi:10.1253/circj.66.987 Google Scholar
  33. 33.
    Abdel-Hamid M, El-Daly M, El-Kafrawy S, Mikhail N, Strickland GT, Fix AD (2002) Comparison of second- and third-generation enzyme immunoassays for detecting antibodies to hepatitis C virus. J Clin Microbiol 40:1656–1659. doi:10.1128/JCM.40.5.1656-1659.2002 PubMedCrossRefGoogle Scholar
  34. 34.
    Abdel-Hamid M, El-Daly M, El-Kafrawy S, Mikhail N, Strickland GT, Fix AD (1990) World Health Organization International classification of diseases and health related problem, 10th revision. World Health Organization, Geneva, SwitzerlandGoogle Scholar
  35. 35.
    Abdel-Hamid M, El-Daly M, El-Kafrawy S, Mikhail N, Strickland GT, Fix AD (2000) World Health Organization International classification of diseases for oncology, 3rd edn. World Health Organization, Geneva, SwitzerlandGoogle Scholar
  36. 36.
    Abdel-Hamid M, El-Daly M, El-Kafrawy S, Mikhail N, Strickland GT, Fix AD (2007) Stata Corporation Stata Statistical Software. Stata Corporation, College Station, TXGoogle Scholar
  37. 37.
    Yu MC, Yuan JM (2004) Environmental factors and risk for hepatocellular carcinoma. Gastroenterology 127:S72–S78. doi:10.1016/j.gastro.2004.09.018 PubMedCrossRefGoogle Scholar
  38. 38.
    McIntyre N (1978) Plasma lipids and lipoproteins in liver disease. Gut 19:526–530. doi:10.1136/gut.19.6.526 PubMedCrossRefGoogle Scholar
  39. 39.
    Jan CF, Chen CJ, Chiu YH, Chen LS, Wu HM, Huang CC, Yen MF, Chen TH (2006) A population-based study investigating the association between metabolic syndrome and hepatitis B/C infection (Keelung Community-based Integrated Screening study No. 10). Int J Obes (Lond) 30:794–799. doi:10.1038/sj.ijo.0803204 CrossRefGoogle Scholar
  40. 40.
    Siagris D, Christofidou M, Theocharis GJ, Pagoni N, Papadimitriou C, Lekkou A, Thomopoulos K, Starakis I, Tsamandas AC, Labropoulou-Karatza C (2006) Serum lipid pattern in chronic hepatitis C: histological and virological correlations. J Viral Hepat 13:56–61. doi:10.1111/j.1365-2893.2005.00655.x PubMedCrossRefGoogle Scholar
  41. 41.
    Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ (2005) Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115:1343–1351PubMedGoogle Scholar
  42. 42.
    Ono M, Saibara T (2006) Clinical features of nonalcoholic steatohepatitis in Japan: evidence from the literature. J Gastroenterol 41:725–732. doi:10.1007/s00535-006-1876-0 PubMedCrossRefGoogle Scholar
  43. 43.
    Hatanaka K, Kudo M, Fukunaga T, Ueshima K, Chung H, Minami Y, Sakaguchi Y, Hagiwara S, Orino A, Osaki Y (2007) Clinical characteristics of NonBNonC-HCC: comparison with HBV and HCV related HCC. Intervirology 50:24–31. doi:10.1159/000096309 PubMedCrossRefGoogle Scholar
  44. 44.
    Hashimoto E, Yatsuji S, Kaneda H, Yoshioka Y, Taniai M, Tokushige K, Shiratori K (2005) The characteristics and natural history of Japanese patients with nonalcoholic fatty liver disease. Hepatol Res 33:72–76. doi:10.1016/j.hepres.2005.09.007 PubMedCrossRefGoogle Scholar
  45. 45.
    Iwasaki M, Otani T, Yamamoto S, Inoue M, Hanaoka T, Sobue T, Tsugane S (2003) Background characteristics of basic health examination participants: the JPHC Study Baseline Survey. J Epidemiol 13:216–225PubMedGoogle Scholar
  46. 46.
    Iwasaki M, Yamamoto S, Otani T, Inoue M, Hanaoka T, Sobue T, Tsugane S (2006) Generalizability of relative risk estimates from a well-defined population to a general population. Eur J Epidemiol 21:253–262. doi:10.1007/s10654-006-0004-z PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2008

Authors and Affiliations

  • Manami Inoue
    • 1
  • Norie Kurahashi
    • 1
  • Motoki Iwasaki
    • 1
  • Yasuhito Tanaka
    • 2
  • Masashi Mizokami
    • 2
  • Mitsuhiko Noda
    • 3
  • Shoichiro Tsugane
    • 1
  • for the Japan Public Health Center-based Prospective Study Group
    • 4
  1. 1.Epidemiology and Prevention DivisionResearch Center for Cancer Prevention and Screening, National Cancer CenterTokyoJapan
  2. 2.Department of Clinical Molecular Informative MedicineNagoya City University Graduate School of Medical SciencesNagoyaJapan
  3. 3.Department of Diabetes and Metabolic MedicineInternational Medical Center of JapanTokyoJapan
  4. 4.TokyoJapan

Personalised recommendations